Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

9.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

621
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
621
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

342
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
342

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends of severe human metapneumovirus infections in India.

BMC infectious diseases·2026
Same author

Disodium cromoglycate restricts human tau hyperphosphorylation and manifestation of associated phenotypes by inhibiting GSK3β activity in Drosophila disease models.

Molecular biology reports·2026
Same author

Interference-aware frequency-agile onboard processor using fine-grained multilevel analysis-synthesis filter-bank channelization.

Scientific reports·2026
Same author

Constant light exposure promotes pathogenic tau hyperphosphorylation and phenotypic manifestations in Drosophila disease models.

Neurochemistry international·2025
Same author

Serum NF-κB-Regulated Biomarkers of Proliferative Lupus Nephritis.

Glomerular diseases·2025
Same author

Targeted downregulation of insulin signaling restricts human tau pathogenesis by reinstating the aberrant heterochromatin loss and mTOR/4EBP/S6K pathway in Drosophila.

Brain research·2024

Related Experiment Video

Updated: Jun 30, 2025

Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

13.6K

Polyglutamine disorders: Pathogenesis and potential drug interventions.

Shweta Tandon1, Prerna Aggarwal1, Surajit Sarkar1

  • 1Department of Genetics, University of Delhi South Campus, Benito Juarez Road, New Delhi 110021, India.

Life Sciences
|March 16, 2024
PubMed
Summary

Polyglutamine (poly(Q)) diseases are neurodegenerative disorders caused by expanded CAG repeats. Research explores therapeutic targets and compounds to combat poly(Q) neurotoxicity across these related conditions.

Keywords:
Animal-modelsInclusion bodiesNeurodegenerationPoly(Q) disordersTherapeutics

More Related Videos

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K
Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans
06:49

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans

Published on: December 17, 2021

2.8K

Related Experiment Videos

Last Updated: Jun 30, 2025

Growth Assays to Assess Polyglutamine Toxicity in Yeast
09:06

Growth Assays to Assess Polyglutamine Toxicity in Yeast

Published on: March 5, 2012

13.6K
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.4K
Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans
06:49

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans

Published on: December 17, 2021

2.8K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Polyglutamine (poly(Q)) diseases are a group of nine inherited neurodegenerative disorders.
  • These conditions arise from expanded CAG trinucleotide repeats in specific genes.
  • Pathognomonic poly(Q) aggregates (inclusion bodies) impair cellular functions, leading to disease.

Purpose of the Study:

  • To review key pathogenic events in poly(Q) diseases.
  • To discuss model system investigations for therapeutic interventions.
  • To list compounds shown to reduce poly(Q)-mediated neurotoxicity.

Main Methods:

  • Literature review of polyglutamine disease pathogenesis.
  • Analysis of model system studies for therapeutic targets.
  • Compilation of experimental data on neuroprotective compounds.

Main Results:

  • Identified critical cellular pathways affected by poly(Q) aggregates.
  • Highlighted the potential of targeting poly(Q) pathogenesis events.
  • Compiled a list of pharmacological and bioactive compounds with demonstrated efficacy.

Conclusions:

  • Poly(Q) diseases share a common etiology, allowing cross-disease therapeutic insights.
  • Targeting specific pathogenic events offers potential treatment strategies.
  • Various compounds show promise in alleviating poly(Q)-mediated neurotoxicity.